William J Hurt1, Mark W Tenforde1,2,3, Mooketsi Molefi4, Hannah K Mitchell1,5, Thandi Milton1, Martin S Azama6, Irene Goercke4, Fredah Mulenga7, Nametso Tlhako1, Katlego Tsholo1, Tuhina Srivastava8, Tshepo B Leeme1,9, Godfrey Simoonga6, Charles Muthoga1,9, Kwana Lechiile1,9, Madisa Mine7, Joseph N Jarvis1,9,10. 1. Botswana University of Pennsylvania Partnership, Gaborone, Botswana. 2. Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. 3. Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, USA. 4. University of Botswana, Gaborone, Botswana. 5. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 6. Ministry of Health and Wellness, Gaborone, Botswana. 7. Botswana National Health Laboratory, Gaborone, Botswana. 8. Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 9. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. 10. Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Abstract
BACKGROUND: Evidence to inform cryptococcal antigen (CrAg)-screening guidelines among ART-experienced populations is lacking. We performed a study evaluating the utility of reflex CrAg screening in Gaborone, Botswana. METHODS: CD4 count data were collected from the HIV reference laboratory from 2014-2016. CrAg screening was performed on samples with CD4 ≤100 cells/µL beginning January 2015. The proportion of CD4 counts ≤100 cells/µL was determined and the frequency of repeat CrAg testing described. Analyses ascertained the impact of ART status on CrAg prevalence and outcomes, and whether CrAg titers could be used for risk stratification. RESULTS: Overall, 5.6% (3335/59 300) of individuals tested had CD4 ≤100 cells/μL; 2108 samples with CD4 ≤100 cells/μL from 1645 unique patients were CrAg tested. Over half of samples were from ART-experienced individuals: 40.9% (863) on ART and 12.1% (255) defaulters; 22% (463) of CrAg tests were on repeat samples. CrAg prevalence was 4.8% (72/1494; 95% CI, 3.8-6.0%) among outpatients and 21.9% (32/151; 95% CI, 15.3-28.5%) among inpatients. CrAg prevalence rates did not differ by ART status, but 6-month mortality was significantly lower in CrAg-positive individuals on ART at screening. Ten CrAg positives were identified through repeat testing. A CrAg titer cutoff ≥1:80 provided the best discrimination for 6-month survival. CONCLUSIONS: CrAg-positivity rates in an ART-experienced population were comparable to those seen in ART-naive populations. Repeat screening identified individuals who seroconverted to CrAg positivity and were at risk of cryptococcal disease. CrAg titers ≥1:80 can help identify the individuals at highest risk of death for more intensive management.
BACKGROUND: Evidence to inform cryptococcal antigen (CrAg)-screening guidelines among ART-experienced populations is lacking. We performed a study evaluating the utility of reflex CrAg screening in Gaborone, Botswana. METHODS:CD4 count data were collected from the HIV reference laboratory from 2014-2016. CrAg screening was performed on samples with CD4 ≤100 cells/µL beginning January 2015. The proportion of CD4 counts ≤100 cells/µL was determined and the frequency of repeat CrAg testing described. Analyses ascertained the impact of ART status on CrAg prevalence and outcomes, and whether CrAg titers could be used for risk stratification. RESULTS: Overall, 5.6% (3335/59 300) of individuals tested had CD4 ≤100 cells/μL; 2108 samples with CD4 ≤100 cells/μL from 1645 unique patients were CrAg tested. Over half of samples were from ART-experienced individuals: 40.9% (863) on ART and 12.1% (255) defaulters; 22% (463) of CrAg tests were on repeat samples. CrAg prevalence was 4.8% (72/1494; 95% CI, 3.8-6.0%) among outpatients and 21.9% (32/151; 95% CI, 15.3-28.5%) among inpatients. CrAg prevalence rates did not differ by ART status, but 6-month mortality was significantly lower in CrAg-positive individuals on ART at screening. Ten CrAg positives were identified through repeat testing. A CrAg titer cutoff ≥1:80 provided the best discrimination for 6-month survival. CONCLUSIONS: CrAg-positivity rates in an ART-experienced population were comparable to those seen in ART-naive populations. Repeat screening identified individuals who seroconverted to CrAg positivity and were at risk of cryptococcal disease. CrAg titers ≥1:80 can help identify the individuals at highest risk of death for more intensive management.
Authors: Hannah K Mitchell; Margaret Mokomane; Tshepo Leeme; Nametso Tlhako; Katlego Tsholo; Chandapiwa Ramodimoosi; Bonno Dube; Kelebeletse O Mokobela; Ephraim Tawanana; Tony Chebani; Pretty Setlhake; Tlhagiso Pilatwe; William J Hurt; Mooketsi Molefi; Paul C Mullan; Andrew P Steenhoff; Madisa Mine; Joseph N Jarvis; Mark W Tenforde Journal: Pediatr Infect Dis J Date: 2019-09 Impact factor: 2.129
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware Journal: Clin Infect Dis Date: 2010-08-15 Impact factor: 9.079
Authors: Radha Rajasingham; Rachel M Smith; Benjamin J Park; Joseph N Jarvis; Nelesh P Govender; Tom M Chiller; David W Denning; Angela Loyse; David R Boulware Journal: Lancet Infect Dis Date: 2017-05-05 Impact factor: 25.071
Authors: Justin Beardsley; Marcel Wolbers; Freddie M Kibengo; Abu-Baker M Ggayi; Anatoli Kamali; Ngo Thi Kim Cuc; Tran Quang Binh; Nguyen Van Vinh Chau; Jeremy Farrar; Laura Merson; Lan Phuong; Guy Thwaites; Nguyen Van Kinh; Pham Thanh Thuy; Wirongrong Chierakul; Suwatthiya Siriboon; Ekkachai Thiansukhon; Satrirat Onsanit; Watthanapong Supphamongkholchaikul; Adrienne K Chan; Robert Heyderman; Edson Mwinjiwa; Joep J van Oosterhout; Darma Imran; Hasan Basri; Mayfong Mayxay; David Dance; Prasith Phimmasone; Sayaphet Rattanavong; David G Lalloo; Jeremy N Day Journal: N Engl J Med Date: 2016-02-11 Impact factor: 91.245
Authors: Mark W Tenforde; Margaret Mokomane; Tshepo B Leeme; Nametso Tlhako; Katlego Tsholo; Tony Chebani; Anya Stephenson; Jemima Hutton; Hannah K Mitchell; Raju Kk Patel; William J Hurt; Tlhagiso Pilatwe; Tiny Masupe; Mooketsi Molefi; Brandon L Guthrie; Carey Farquhar; Madisa Mine; Joseph N Jarvis Journal: Lancet Infect Dis Date: 2019-07 Impact factor: 71.421
Authors: Nicky Longley; Joseph Nicholas Jarvis; Graeme Meintjes; Andrew Boulle; Anna Cross; Nicola Kelly; Nelesh P Govender; Linda-Gail Bekker; Robin Wood; Thomas S Harrison Journal: Clin Infect Dis Date: 2015-11-12 Impact factor: 9.079
Authors: Mark W Tenforde; Thandi Milton; Ikanyeng Rulaganyang; Charles Muthoga; Leabaneng Tawe; Tom Chiller; Gregory Greene; Alexander Jordan; Christopher G Williams; Leah Owen; Tshepo B Leeme; Amber Boose; Julia Ngidi; Madisa Mine; Joseph N Jarvis Journal: Clin Infect Dis Date: 2021-05-04 Impact factor: 9.079
Authors: Joseph Baruch Baluku; Pallen Mugabe; Shem Mwebaza; Jane Nakaweesi; Catherine Senyimba; Joel Peter Opio; Barbara Mukasa Journal: Open Forum Infect Dis Date: 2021-01-06 Impact factor: 3.835
Authors: Joseph N Jarvis; Mark W Tenforde; Kwana Lechiile; Thandi Milton; Amber Boose; Tshepo B Leeme; Leabaneng Tawe; Charles Muthoga; Ivy Rukasha; Fredah Mulenga; Ikanyeng Rulaganyang; Mooketsi Molefi; Síle F Molloy; Julia Ngidi; Thomas S Harrison; Nelesh P Govender; Madisa Mine Journal: J Clin Microbiol Date: 2020-08-24 Impact factor: 5.948